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Objective and background: Longterm adherence to inhaled corticosteroids is poor 
despite the crucial role of preventer medications in achieving good asthma outcomes. 
This study was undertaken to explore patient preferences in relation to their current 
inhaled corticosteroid  medication, a hypothetical preventer or no medication  
Methodology: A discrete choice experiment (DCE) was conducted in 57 adults with 
mild-moderate asthma and airway hyperresponsiveness, who were using inhaled 
corticosteroid 500µg/day (beclomethasone equivalent). In the DCE, subjects 
evaluated 16 hypothetical scenarios made up of ten attributes that described the 
process and outcomes of taking asthma medication, with 2-4 levels for each attribute. 
For each scenario, subjects chose between the hypothetical medication, the 
medication they were currently taking and no asthma medication. A random 
parameter multinomial logit model was estimated to quantify subject preferences for 
the aspects of taking asthma medication and the influence of attributes on medication 
decisions. Results: Subjects consistently made choices in favour of being able to do 
strenuous and sporting activities with or without reliever, experiencing no side effects 
and never having to monitor their peak flow.  Frequency of collecting prescriptions, 
frequency of taking the medication, its route of administration, and the strength of the 
doctor recommendation about the medication were not significant determinants of 
choice. Conclusions: The results of this study suggest that patients prefer a preventer 
which confers capacity to maximize physical activity, has no side effects and does not 
require daily peak flow monitoring.   
Keywords: patient preferences, asthma 
Short title: Subject preferences for preventive asthma medication 
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Asthma patients’ willingness to comply with treatments prescribed by their physician 
plays a critical role in their management. 1-3 Anecdotal evidence suggests that 
patients’ preference may be influenced by many factors in addition to clinical 
measures of effectiveness generally considered to be important by physicians.4 In 
view of this, information on patients’ preferences for different medications and the 
aspects of taking medication they do or do not like could be used by physicians when 
making prescribing decisions. This information may contribute to improved 
adherence with medication use and may also be of use when designing new 
medications.  
 
The investigation of individuals’ preferences, using stated preferences elicited in 
response to hypothetical choices under controlled experimental conditions, is well 
established in marketing research, transport and environmental economics.5 These 
techniques have increasingly been used to study patient preferences across health 
programs.6 7 To date, this approach has been used to explore preferences for different 
types of asthma symptoms 8, characteristics of service delivery for asthma care 9, the 
impact of the speed and duration of action of medication for asthma 10 and the 
personal impact of exacerbations of COPD.11 The earlier studies used pairwise 
comparisons while in the Johannson study, alternative treatments were ranked. 
Neither of these approaches allows patients to compare the offered treatment with no 
treatment, yet the extent of non-adherence to medication regimens suggests that in 
many cases patients prefer taking no medication to the treatment prescribed. 
 
The aim of this study was to assess preferences for asthma medications by patients 
who were currently using an inhaled corticosteroid as their preventer. This discrete 
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5choice experiment extended the work of the above studies by considering a broader 
range of the effects of medication, including symptom relief, side-effects, 
convenience and cost. Further, it allowed participants to opt-out of the forced choice 
between two alternatives by including a “no medication” alternative. We investigated 
how patients make trade-offs across different attributes, and we modelled the changes 
in the probability of choosing medication as the attributes changed.  We were also 
interested in the value patients place on different attributes and so we modelled the 




This discrete choice experiment (DCE) was carried out at the commencement of a 
multicentre, randomised controlled trial of three preventive asthma medications as 
reported elsewhere.12 The trial was conducted in Sydney and Melbourne, Australia, 
between February 2001 and August 2002. The protocol for the study, including the 
DCE component, was approved by the ethics review committee for each site, and all 
subjects provided written informed consent.  The trial subjects were aged 16-74 years, 
and had mild-moderate airway obstruction and hyperresponsiveness to methacholine 
and symptomatic asthma. Subjects were excluded from screening if they had 
significant other lung disease, were current smokers or had a smoking history of 10
pack years, a history of severe asthma or a recent exacerbation.  This paper reports 
results for subjects who were using inhaled corticosteroids at screening, not more than 
500µg/day (beclomethasone equivalent). Screened subjects who were not taking 
regular preventer medications were excluded from the present analysis.  
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Subjects completed a self-administered questionnaire at the screening visit before they 
underwent any study procedures or received any feedback about their asthma from 
study staff.   The questionnaire comprised demographic questions, a “report card” 
(questions about respondents’ current medication which related to the attributes and 
levels used in the DCE), and a set of DCE scenarios. The latter generated the 
preference data by presenting respondents with a series of hypothetical scenarios, with 
attribute levels varying systematically according to an experimental design. The 
rationale for this approach was that any product or program can be described in terms 
of its underlying characteristics or attributes, and individuals’ preferences for these 
attributes can be inferred by observing their choices as the attribute levels vary. In 
this study, respondents were presented with a hypothetical medication, described in 
terms of its underlying attributes, and chose among three alternatives: 1) their current 
medication; 2) the medication described in the hypothetical scenario; and 3) no 
preventive medication.  An example of a scenario and choice question, together with 
the instructions for completion, are contained in Appendix 1.     
 
Development of the attributes and experimental design 
Attributes and levels associated with the choice of asthma medication were identified 
from the literature and discussions with respiratory physicians. A series of structured 
interviews with asthmatic patients attending a respiratory clinic identified missing 
attributes and the importance of those selected.  The preliminary list of attributes and 
the questionnaire were then pilot tested. From this, ten attributes, seven with four 
levels and three with two levels, were included in the final design. These attributes 
and their levels are shown in Table 1.  
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7Although each respondent could complete a number of scenarios, with this number of 
attribute/levels (combinations of attribute levels; in this case 131,072), it was 
necessary to use a fractional factorial design. We selected 256 scenarios which 
included all levels of all attributes, with pharmacologically implausible combinations 
of attributes excluded. The resulting design was nearly orthogonal and balanced in 
terms of the number of times each level of an attribute was seen.  The 256 scenarios 
were divided randomly into 16 versions of the questionnaire, each including 16 
scenarios, and subjects were randomly assigned to a version for completion. Pilot 
testing suggested respondents understood the material presented and were able to 
complete the questionnaire without difficulty or assistance.   
 
Analysis 
The results were analysed using the random parameter multinomial or mixed logit 
(MXL) model similar to the method and specification of Hall et al 13, with some 
notable exceptions.  First, in this study we used information about each participant’s 
current medication (as per the report card) as part of the model estimation. Second, 
only the intercepts were assumed to be random due to the limitation of the sample size 
in this study; a larger sample size would have allowed estimation of random attribute 
parameters as well.  Further detail about the econometric analysis is given in the 
appendix two.  
 
The model results were used to estimate the effect of changes in attribute levels on the 
probability of patients choosing a particular treatment alternative. To do this, we 
defined a base case and then systematically changed attribute levels. With this model, 
the alternative specific intercepts by themselves represent a natural base as they 
correspond to an average case. This interpretation derives from setting the cost and 
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8trips to chemist attributes of both current and hypothetical medication to their average 
level values in the experimental design and from using effects coding for the 
remaining attributes.  For cost we simulated the effect of a $30 reduction in cost for a 
three month supply and for trips to the chemist over a six month period we simulated 
an increase of one trip. All other attributes had distinct levels and were simulated as 
such.  
 
Table 1: Attributes and levels of the discrete choice experiment and report card 
 
The model results were also used to estimate the value patients attach to individual 
attributes by calculating the compensating variation (referred to more generally as 
willingness to pay (WTP)) for improvements in each attribute 14. This involved 
estimating the WTP for a move from one level of an attribute to another level of the 
same attribute.  Further detail about the method of WTP simulation is provided in the 




Fifty seven subjects (27 female, 30 male) were eligible for this analysis. These 
subjects had an average age of 43 years (range 16-74 years) and a median family 
income of $50,001AUD-$60,000. Mean FEV1 at entry was 82.6% predicted (95% 
confidence interval 78.8 – 86.5%). Their responses to the report card questions, 
describing their current medication, are given in the last column of Table 1. 
Approximately equal numbers of participants stated they were using their preventer 
medication once or twice a day, and almost one third reported experiencing occasional 
hoarseness of speech. Most participants could carry out any sporting or strenuous 
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9activity that they wanted, either with (58%) or without (23%) the use of a reliever.  
 
Fifty five subjects responded to all 16 scenarios, and a further two subjects missed one 
scenario each, giving a total of 910 observations. Of these, “current medication” was 
chosen for 80% of scenarios; “hypothetical medication” was chosen for 13%; and “no 
medication” was chosen for 6%. There were 11 respondents (19%) who chose their 
current medication for all 16 scenarios. These respondents were not excluded from the 
analysis since they can be accommodated within random utility theory [7]. 
 
Analysis of the Preference Data  
The results of the mixed logit model with generic attributes and two random intercepts 
are presented in Table 2.  A number of the attribute coefficients were statistically 
significantly different from zero and their sign and size were as expected. These are 
the attributes that are likely to be relevant to subjects when making decisions between 
asthma medications: cost, symptoms, side effects, daily activities, sporting activities 
and monitoring peak flow. Increasing cost, reduced participation in sports, restriction 
to only a few usual daily activities despite taking reliever, and frequent night waking 
because of asthma each reduced the likelihood that the subject would choose the 
hypothetical medication.  When choosing between medications, subjects preferred not 
to have to monitor their peak-flow.  The occurrence of side-effects was also a 
significant attribute, with participants being significantly less likely to choose a 
medication associated with tremors, palpitations, nervousness, headache or oral thrush. 
Occasional hoarseness of speech was the side effect that affected choice the least, 
seen best by referring to table 3, showing the relative impact of different side effects. 
A hypothetical medication would be more likely to be chosen if occasional hoarseness 
occurred than if tremors or Candida were side effects. In summary, subjects 
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consistently made choices in favour of being able to do strenuous and sporting 
activities, having no restriction on normal activities, no night waking, experiencing no 
side effects and never having to monitor their peak flow. 
 
Table 2: Estimated Mixed Logit model 
 
Most of the attributes associated with convenience, that is, frequency of collecting 
prescriptions, frequency of taking the medication and the route of administration of 
the medication (tablet or inhaler), were not significant determinants of choice. 
Similarly, the strength of the doctor recommendation about the medication was also 
not significant. 
 
The coefficients of the random intercepts in the mixed logit measure the inherent 
preferences of the respondents for taking medication. The common medication 
intercept (preference for taking either current or hypothetical over no medication) has 
neither the mean nor standard deviation significantly different from zero.  In contrast, 
the current medication intercept (preference for taking current medication over 
hypothetical)  was significantly greater than zero, and its standard deviation was also 
significant and large relative to the mean.  
 
Simulated probabilities of choosing medication alternatives 
Respondents displayed a clear preference for their current medication, as reflected in 
the simulated base case (Table 3).  The probability of choosing the current medication 
base case was 0.56, and it was 0.35 for the hypothetical base case.  Since the attribute 
levels of the current medication and hypothetical base cases were both set to the 
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average values in the experimental design, the difference between their predicted 
probabilities reflect an inherent preference for current treatment, or the status quo. We 
note that the preference for current medication in the simulations (with a predicted 
probability of 0.56) was considerably less than the rate observed in the choice 
experiment, where current medication was chosen in 80% of 910 scenarios. This is 
because the simulated current medication base (which was at the experimental design 
average) was less attractive than the average of the patients' actual current 
medications (as described in the report card).   
 
Table 3: Effect of attributes on the predicted probabilities of choosing each 
medication alternative  
Table 3 also shows the effects of attributes on the predicted probability of choosing 
each medication alternative. For example, when assuming the hypothetical medication 
causes no side effects, this medication becomes more attractive to respondents and the 
probability of choosing the hypothetical medication increases from the base level of 
0.35 to 0.58.  The current medication attributes are still at their base (average) level of 
side-effects, making the current medication less attractive than the hypothetical 
medication, and the probability of choosing current medication falls from 0.56 to 
0.34. The attributes which had the greatest effect on choice probabilities were side-
effects, symptoms and activities. 
 
The probability of choosing no medication when both the current and hypothetical 
medications were set to the base case was 9%, not dissimilar to the opt-out rate in the 
preferences data (6%).  Further, this did not vary much as attributed levels of the 
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hypothetical medication were varied; most of the shift in preferences was between 
current and hypothetical medications in these simulations.  
 
Simulated willingness to pay 
The WTP for improvements in individual attributes are presented in Table 4 and relate 
to a three month prescription. The WTP to improve participation in sporting and 
strenuous activities from reliever being necessary to being able to participate in all 
activities without difficulty was $39.82.  Improving symptoms from having exercise-
related breathlessness, cough or wheeze once a week to minimal symptoms once a 
week or less had a WTP of $52.57.  Table 4 shows that WTP to eliminate two of the 
side effects (tremors, palpitations, nervousness or headache and oral thrush) is 
relatively high.  Moving from all daily activities with reliever to all without had a 
small WTP.   
 




Our results confirm and extend the findings of other patient preference studies, using 
DCE and other models, indicating that patients value particular characteristics 
conferred by preventer medications. These include the ability to participate in 
strenuous activity, have no restriction of daily activities, have no night waking and be 
free of side effects. The results from this DCE are clinically plausible, and should 
inform clinicians about patient priorities that might assist with adherence and appeal 
to a rational understanding of the cost-benefit of preventer medication for asthma. 
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Several aspects of asthma treatment identified as important by patients in this study, 
such as effectiveness of treatment and freedom from side effects have also been 
identified in studies which have not employed DCE 15-17 as well as those that have .8 10 
These results are not surprising, but the knowledge should assist physicians when 
advocating preventer medications to patients, as highlighting these benefits is likely to 
help patients adhere to treatment. 
 
In this study, patients demonstrated a strong tendency to choose the current 
medication, a status quo effect also noted by other studies, but not universally so.10 On 
average, the hypothetical medications were less desirable than the current medication 
(as reported in the report card), a significant observation in that subjects were only 
eligible if they were currently taking inhaled corticosteroids as preventer medication.  
However, the average number of repeats (usually a month’s supply) which were 
collected in a 6 month period (2.2) and the average cost for 3 months suggests a high 
level of non-compliance with their prescribed medication by these subjects. This may 
be a result of an inevitable “disconnect’ between adherence in theory and practice, 
where despite good intentions, patients still fail to take inhaled corticosteroids as 
prescribed.   
 
The coefficients of the random intercepts in the mixed logit have an interesting 
interpretation.  The results on the common medication intercept indicate that 
medication (whether current or hypothetical) was not valued over no medication per 
se. In contrast, the current medication intercept (mean significantly greater than zero, 
and significant and large standard deviation) implies that while, on average, 
respondents preferred current medication over the hypothetical medication, there was 
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substantial variation among individuals and some individuals may have preferred the 
hypothetical medication.   
 
In addition to clinical relevance of this study there are several methodological 
strengths of the DCE design we used. First, we provided three alternative choices, 
allowing an opt-out or no medication option. Interestingly, this was chosen in only a 
minority of scenarios (6%), perhaps reflecting the inclusion and exclusion criteria for 
this sample (all subjects regularly used preventer medication).  Second, we used a 
report card to record information about each subject’s usual preventer medication. 
This information was used in the model estimation, so the coefficient estimates reflect 
patients’ preferences relative to their status quo.  Third, we made the model 
coefficient estimates more interpretable by converting them into choice probabilities 
which embody the relative importance patients place on issues such as symptoms and 
side-effects.  
 
Simulation of WTP is another approach to illustrate the tradeoffs patients were 
prepared to make across attributes and provide a measure of the monetary value 
patients attach to individual attributes and there were no unexpected findings.  
Johansson et al found estimates of WTP that were either similar to actual treatment 
costs or higher, suggesting patients have a realistic notion of the relative “dollar” 
value of positive treatment attributes. In the current study, we used treatment costs in 
the range of $0 to $100, compared to the average cost of $25 per 3 month period 
experienced by patients in the study. Our estimates of WTP indicated participants 
were willing to pay $40 to $50 to reduce symptoms to minimal, and $20 to $60 
(depending on symptom level) to increase their participation in all activities. It is 
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noteworthy that patients were willing to pay very large sums for freedom from side 
effects, namely $190 for no tremor and $135 for no oral thrush. Interestingly, the 
change from all activities with reliever to none with reliever was regarded as having 
low value, suggesting patients are accustomed to using reliever and do not necessarily 
regard its absence as a high priority in their management goals. 
 
At first sight the finding of a positive coefficient for occasional hoarseness may be 
surprising. However, this is relative to the other side effect options. The results 
suggest that the patients in this study regarded this symptom as the least unpleasant 
amongst the symptoms offered in the scenarios – apart from no side effects, the 
possible responses included tremors, palpitations, nervousness or headache, oral 
thrush, or occasional hoarseness of speech. In other studies of patient preferences, side 
effects were rated as very important, particularly the adverse effects of inhaled 
corticosteroids.18 19 Given the low adherence rates reported in many countries with 
inhaled corticosteroids 20, this appears to be a real issue limiting the potential gains to 
be made by compliance with preventer medications.     
 
The study sample size was relatively small, however a key advantage of the DCE 
method is its efficiency.  Several of the attributes were statistically significant; 
highlighting that lack of power was not a concern.  Further, all discrete choice surveys 
have to strike a balance between comprehensiveness of attribute descriptions and 
respondent burden and pilot testing reflected favourably on this balance.  
 
The study was limited to mild-moderate asthmatics who volunteered for a clinical 
trial. Their reported expenditure on medications and baseline quality of life results 
suggest that asthma did not have a major impact on their lives. Consequently, these 
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respondents may not be representative of asthmatics more broadly, and this may limit 
the generalisability of the findings. Although the survey design elicited multiple 
responses from each individual, the small sample size meant we were not able to fully 
explore heterogeneity in preferences across individuals. Nevertheless, the results 
provide valuable information for designing treatment plans and predicting who will 
comply.  
 
This study makes an important contribution to the literature about patient preferences 
for preventive asthma medications and the relative importance they place on a wide 
range of treatment outcomes, both positive and negative. By developing the scenarios 
and options through patient and clinician interviews, we were able to incorporate 
clinically important factors that both patients and clinicians indicated were likely to 
affect treatment choice and compliance. The scenarios focused on a wide range of 
medication attributes that have direct relevance to patient quality of life [12], and the 
results of the study should inform clinical decision making and assist in effective 
communication with patients. The benefits of shared decision making can be 
enhanced by clinician awareness of patient priorities 21, and the results from this study 
offer further information to help clinicians achieve better asthma outcomes in 
partnership with patients.  
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Table 1: Attributes and levels of the discrete choice experiment and report card 
 
Attribute Description Levels Report card responses 
Process Attributes 
Cost1 Total cost of the drug to 
you for a (3) month 
supply is: 
$0; $20; $80; $100 Average  
cost: $A25 
Repeats In order to pick up your 
prescription and repeats 
for each 6 month period 
you will have to go to the 
chemist2:
Once; twice; 3 times; 6 times Average  
repeats: 2.2 
• an aerosol inhaler 54% 
• a dry powder inhaler, e.g. Turbuhaler 
or Accuhaler 
46% 
• a tablet 0% 
Administration You take the drug via: 
• both an inhaler and a tablet 0% 
• once a day 53% How often You need to take the 
drug: • twice a day 46% 
• every morning 23% Monitoring You measure your 
morning peak flow: • never 77% 
Health Outcomes   
• minimal symptoms once a week or 
less 
26% 
• exercise breathlessness, cough or 
wheeze once a week 
35% 
• chest tightness doing normal activities 




On this drug you will 
experience: 
• awaking at night with asthma 
requiring the use of reliever more 
than 4 times a week 
12% 
• all usual daily activities without the 
use of a reliever 
32% 
• all usual daily activities provided you 
use a reliever for some of these 
activities 
60% 
• most usual daily activities provided 




Compared to most people 
in your age group you are 
able to participate in: 
• a few usual daily activities provided 
you use a reliever all the time 
2% 
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Table 1 continued 
 
1 Amounts are quoted in Australian dollars ($AUS) ), the report card question asked how much subjects currently 
paid for a 3 month supply of preventer medication and did not constrain responses to the levels used on the cost 
attribute in the DCE. 
2 “Chemist” = pharmacist or drug store 
 
• all the sporting or strenuous activity 
you want without difficulty 
23% 
• all the sporting or strenuous activity 
you want with the use of reliever 
58% 
• a restricted range of the sporting and 
strenuous activity you want with the 




You are able to 
participate in: 
• no sporting or other strenuous 
activity 
4% 
• no side effects 56% 
• tremors, palpitations, nervousness 
or headache 
3% 
• oral thrush 11% 
Side effects On this drug you 
will experience: 
• occasional hoarseness of speech 30% 
Inputs   
• is the best for your asthma 28% Dr recommendation Your doctor says 
that this drug:  
• will give you satisfactory control of 
your asthma 
72% 
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Table 2: Estimated Mixed Logit model 
 
Notes: 
1.*** Significant at 1% level;  ** Significant at 5% level;  * Significant at 10% level. 
2. Pseudo R2 (McFadden’s R2) is defined as 1 – (LL/LL0), where LL is the value of the (simulated) log-
likelihood function evaluated at the estimated parameters while LL0 is the value of the log-likelihood 
function for a base model that only contains a non-random alternative-specific intercepts.   
3. In the estimation, Cost and trips to the chemist are continuous and mean centered; other attributes are 
effects coded [5]. 
4. A negative sign for a particular attribute level implies that level impacted negatively on utility and 
therefore reduced the probability of choosing the current or hypothetical medication with that level. In 
general, the signs of the attributes were as expected.  
 
Variables Description Coefficients Standard 
error 
Common medication intercept Mean 11.53 7.75 
Standard Deviation 9.05 5.61 
Current medication intercept Mean 0.73* 0.39 
Standard Deviation 1.96*** 0.38 
Cost  -0.015*** 0.005 
Trips to the chemist  0.059 0.086 
Administration Aerosol inhaler 0.26 0.18 
Powder inhaler 0.11 0.25 
Tablet -0.0031 0.20 
Inhaler & tablet -0.37* 0.21 
Frequency of taking the drug  Once per day 0.11 0.16 
Twice per day -0.11 0.16 
Symptoms Minimal 1.23*** 0.27 
Cough, wheeze, etc. 0.36* 0.21 
Chest tightness -0.34* 0.18 
Waking at night -1.25*** 0.23 
Dr Recommendation Best for your asthma -0.011 0.12 
Satisfactory control` 0.011 0.12 
Usual daily activities All without reliever 0.43* 0.23 
All with reliever 0.47* 0.25 
Most with reliever 0.081 0.24 
Few with reliever -0.98*** 0.24 
Sporting/strenuous activities All without difficulty 1.41*** 0.26 
All with reliever 0.76*** 0.24 
Restricted with reliever -0.61** 0.27 
None -1.56*** 0.26 
Monitoring peak flow Every morning -0.29** 0.14 
Never 0.29** 0.14 
Side effects None 1.58*** 0.29 
Tremors, etc. -1.67*** 0.47 
Oral thrush -0.67** 0.32 
Occasional hoarseness 




-281.9074   
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Table 3: Effect of attributes on the predicted probabilities of choosing each 
medication alternative  
Notes: 
1. The base probability represents the case where all attributes levels were set to the average values in 
the experimental design. 
2. The effect of each attribute level on predicted probabilities is calculated by setting the hypothetical 
medication to that particular level (see methods for more detail).  The degree of change relative to the 








Base probability1 0.56 0.35 0.093 
Attribute Hypothetical set to this 
level   
Cost $30 reduction 0.49* 0.42* 0.089 
Trips to the chemist Increase of one visit 0.55 0.36 0.092 
Administration Aerosol inhaler 0.52 0.39* 0.091 
Powder inhaler 0.54 0.37 0.092 
Tablet 0.56 0.35 0.093 
Inhaler & tablet 0.60 0.30* 0.095 
Frequency of taking 
the drug  
Once per day 
0.54 0.37 0.092 
Twice per day 0.57 0.34 0.093 
Symptoms Minimal 0.39** 0.53*** 0.082* 
Cough, wheeze, etc. 0.51 0.40* 0.090 
Chest tightness 0.60 0.31* 0.095 
Waking at night 0.70** 0.20** 0.100 
Dr Recommendation Best for your asthma 0.55 0.35 0.092 
Satisfactory control 0.56 0.35 0.093 
Usual daily activities All without reliever 0.50* 0.41* 0.089 
All with reliever 0.49* 0.42* 0.089 
Most with reliever 0.54 0.36 0.092 
Few with reliever 0.67** 0.23** 0.099 
Sporting/strenuous 
activities 
All without difficulty 
0.36** 0.56*** 0.080* 
All with reliever 0.45* 0.46** 0.086 
Restricted with reliever 0.63* 0.27** 0.097 




0.59 0.31* 0.095 
Never 0.52 0.39* 0.090 





Oral thrush 0.64* 0.26** 0.097 
Occasional hoarseness 
of speech 0.45* 0.46** 0.086 
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Table 4: Willingness to pay (WTP) for a three month period for improvements in 
individual attributes 
Attribute Improvement in the attribute WTP/3 months 
Monitoring peak flow Every morning to never $35.04 
Sporting/strenuous 
activity 
None to a restricted range $55.94 
A restricted range to all with reliever $81.56 
All with reliever to all without 
difficulty 
$39.82 
Usual daily activities Few with reliever to most with 
reliever 
$62.52 
Most with reliever to all with 
reliever 
$23.32 
All with reliever to all without 
reliever 
$2.68 
Symptoms Waking at night to chest tightness $53.19 
Chest tightness to cough etc $41.77 
Cough etc to minimal symptoms $52.57 
Side effects Tremors to no side effects 
 
$193.49 
Oral thrush to no side effects $135.52 
Hoarseness to no side effects $49.55 
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APPENDIX 1: Example choice set  
Total cost of the drug to you for a 3 month 
supply is: 
Free 
In order to pick up your prescription and 
repeats for each 6 month period you will 
have to go to the chemist: 
Twice 
You take the drug via: a tablet 
You need to take the drug: Once a day 
On this drug you will experience: Exercise breathlessness, cough or wheeze 
once a week 
Your doctor says that this drug: is the best for your asthma 
Compared to most people in your age 
group you are able to participate in: 
all usual daily activities without the use of 
a reliever 
You are able to participate in: all the sporting or strenuous activity you 
want without difficulty 
You measure your morning peak flow: Never 
This drug will cause: no side effects 
Suppose you had the option of taking the medication described in the situation  
above.  Considering how severe your asthma is, which option would you prefer 
out of: 
 
1 Your current preventer medication  
2 The preventer medication in the situation above 
3 No preventer medication 
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APPENDIX 2: Online supplement  
USING DISCRETE CHOICE EXPERIMENTS TO INVESTIGATE SUBJECT 
PREFERENCES FOR PREVENTIVE ASTHMA MEDICATION 
 
Econometric Analysis 
The statistical analysis of choice data relies on the random utility model 22, where 
each respondent faces a choice amongst J alternatives or options repeated under S
scenarios or choice situations. The utility that individual i derives from alternative j in 
scenario s is composed of systematic and random components denoted by 
 
isjiisjisj XU  +=)1(
where Xisj is a K x 1 vector of explanatory variables and i is a conformable vector of 
coefficients. 
 
This gives the standard multinomial logit (MNL) specification, conditional on i, and 
assuming the disturbance terms isj to be identically and independently distributed 
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In general, variability (or heterogeneity) among people is expected.  Heterogeneity is 
a result of the variation in behavior across individuals that can be attributed to their 
differences in tastes and decision making processes.  The MNL specification can be 
generalized to account for this heterogeneity by allowing components of  to vary 
over individuals but not over the repeated choices made by an individual. The effect 
of this is to introduce error correlation across choice situations, accounting for the 
dependence structure in unobserved utility among the repeated choices of an 
individual that comes from the panel structure of the data.  This correlation is not 
perfect because of the presence of the independent extreme value term isj. This 
specification also induces correlation across the alternatives in each choice situation 
as long as generic attributes appear in the utility specifications for these alternatives. 
 
The resultant random parameter or mixed logit (MXL) model used in this analysis is 
similar to the method and specification of Hall et al 13, with some notable exceptions.  
First, in this study we utilized information about the participant’s current medication 
as part of the model estimation. This information was recorded in a “report card”, a 
set of self-complete questions included in the questionnaire whereby participants 
described their current medication in terms of the same attributes and levels as in the 
discrete choice experimental design.  Second, in this paper only the intercepts were 
assumed random due to the limitation of our sample size in this study, while in the 
study by Hall et al, a larger sample size allowed estimation of random attributes as 
well.   
 
Estimation by maximum simulated likelihood (MSL) was undertaken using a program 
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downloaded from Kenneth Train's website1. All estimation results reported in this 
paper were generated assuming the random parameters were normally distributed and 
using 1000 Halton draws to simulate the likelihood functions to be maximized 24.
Simulation of predicted probabilities 
 
We simulated the impact on probabilities by varying the level of one attribute at a 
time for the hypothetical medication (note the attribute levels of the current 
medication were not changed from the base level. Thus we were simulating the 
impact of a change in desirability of the hypothetical medication (caused by, for 
example, an increase in its cost or side-effects) on the probability of a participant 
selecting the hypothetical medication, and consequently the probability of the other 
two alternatives being selected.   
 
Taking 1000 random draws from the estimated distributions of the random parameters, 
probabilities were simulated using equation (2) and the reported predictions calculated 
as means over these 1000 replications. 
 
Simulation of willingness to pay 
The willingness to pay is also referred to as the compensating variation (CV).  The 
CV associated with moving from an initial state in which the attributes are described 
by a particular level to another in which one or more of the attribute levels have been 
improved can be expressed as  
 
1 http://elsa.berkeley.edu/Software/abstracts/train0296.html 
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in which 0jV and 
1
jV are the estimated value of equation (1) before and after the 
attribute improvement respectively and the difference in these is weighted by the 
inverse of the coefficient on the price attribute14.
Similar to the simulation of the predicted probabilities, taking 1000 random draws 
from the estimated distributions of the random parameters, the WTP values were 
simulated using equation (3) and reported WTP calculated as means over these 1000 
replications.   
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